Abstract The present invention provides compositions comprising amorphous form of Olmesartan Medoxomil and methods of manufacture. The amorphous form was made by the process of hot melt extrusion or other thermal means. Formulated amorphous dispersions shows enhanced solubility, dissolution rate and bioavailability. The resultant homogeneous amorphous drug embedded polymeric matrix can be successfully transformed into suitable oral pharmaceutical dosage from like pellets, granules, immediate and modified release tablets, oral fast dissolving systems.
